Construction method of mouse salmonella enteritidis strain Ssq infection model for evaluating curative effect of in-vivo norfloxacin

By constructing a mouse infection model and combining with Salmonella enteritidis SEF14 pili-specific antibody detection, the complexity and accuracy of the evaluation of the therapeutic efficacy of norfloxacin was solved, and the accurate evaluation of Salmonella enteritidis was achieved, which was suitable for different strains. and applications in animals.

CN118903213APending Publication Date: 2024-11-08YANGZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411277589.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing methods for evaluating the efficacy of Salmonella enteritis infection have complexity, low specificity, high cost and inaccurate results, especially when it is difficult to accurately evaluate the efficacy when treated with norfloxacin.

Method used

A mouse infection model was constructed, and the dynamic changes of antibodies were monitored to evaluate the efficacy by oral infection of S. enteritidis strain Ssq and treatment with norfloxacin. .

Benefits of technology

The precise evaluation of the therapeutic effect of norfloxacin can be achieved, and can be extended to different strains and different animals, improving the specificity and convenience of the evaluation, and ensuring the accuracy of the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903213A_ABST
    Figure CN118903213A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a salmonella enteritidis strain Ssq in construction of a mouse infection model for evaluating the treatment effect of norfloxacin in vivo. The invention also discloses a construction method of a salmonella enteritidis strain Ssq infected animal model for evaluating the in-vivo treatment effect of norfloxacin, and a specific evaluation method for the in-vitro treatment effect of norfloxacin in a norfloxacin sensitive salmonella enteritidis infected mouse. Accurate evaluation of the curative effect of norfloxacin in mice on salmonella enteritidis is realized, and the method can be further applied to evaluation of different salmonella enteritidis in vitro and evaluation application of salmonella enteritidis in different animals and human bodies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the fields of biomedicine and biotechnology, and particularly relates to a method for constructing a mouse Salmonella enterica serovar Ssq infection model for evaluating the efficacy of norfloxacin in vivo. Background Art

[0002] Salmonella Enteritidis (SE) is an important foodborne zoonotic pathogen that can cause symptoms such as gastroenteritis and food poisoning in humans or animals, and even cause death in severe cases, causing huge economic losses to poultry / livestock breeding and production, and seriously threatening public health. Norfloxacin, as a synthetic third-generation quinolone antibacterial drug, kills bacteria by inhibiting the synthesis of DNA gyrase and topoisomerase of pathogenic bacteria, and is a commonly used drug for the treatment of human enteritis and dysentery. With the irrational and irregular use of antibiotics such as norfloxacin, the cumulative impact continues, and SE resistance has increased year by year, resulting in poor intervention efficacy or treatment failure, further potentially threatening the health development of poultry / livestock breeding and production. The rational use of antibiotics such as norfloxacin and accurate evaluation of their efficacy in vivo are key measures to prevent SE infection.

[0003] At present, the classic method for evaluating the efficacy of anti-SE infection is to evaluate the efficacy of antimicrobial drugs in vivo by calculating the changes in the number of enteritidis Salmonella in individual tissues, organs / host cells of infected animals before and after antimicrobial treatment. However, this method still has many shortcomings. For example, the infected animals need to be properly killed during the implementation process, which makes the evaluation method complicated; some animals and individual animals are not susceptible to enteritidis Salmonella, which makes the specificity and sensitivity of the evaluation method poor; susceptible animals such as large animals need to be used, which makes the evaluation method expensive; enteritidis Salmonella takes a long time to culture in vitro, which makes the method time-consuming and difficult to operate. Most importantly, there is a lack of good consistency between most animal evaluation results and the actual efficacy of antimicrobial drugs. Although clinical trials using mice are used to evaluate the efficacy of antibiotics against enteritidis Salmonella, they involve multiple enteritidis Salmonella strains and multiple drugs, and are limited by the above factors, resulting in inaccurate, non-specific and inconvenient evaluation results. Summary of the invention

[0004] Purpose of the invention: The technical problem to be solved by the present invention is to provide an application of the Enteritidis Salmonella strain Ssq in constructing a mouse infection model for evaluating the in vivo therapeutic efficacy of norfloxacin.

[0005] The technical problem that the present invention also aims to solve is to provide a method for constructing a mouse infection model for evaluating the in vivo therapeutic efficacy of norfloxacin.

[0006] The present invention constructs a specific and convenient method for accurately evaluating the efficacy of norfloxacin in mice infected with norfloxacin-sensitive enteritis Salmonella Ssq strain in vitro. The method specifically orally infects mice with SE Ssq strain, and uses a classic enteritis Salmonella separation, identification and counting method to prove the continuous existence and number of SE Ssq strains in mice. At the same time, a detection and monitoring method for enteritis Salmonella SEF14 pili-specific antibodies is used to prove the SEF14 pili antigen-specific immune response in infected mice, pili antibody production, and continuous increase in antibodies in infected mice, and antibody agglutination titer levels. Under norfloxacin treatment, the infected mice have consistent SEF14 pili antigen-specific immune response, pili-specific antibody production, antibody dynamic changes, and disappearance of antibody agglutination titers with the presence, proliferation decline or disappearance of SE Ssq strains in mice, and the results of classic separation, identification and counting of pathogens in infected mice. The detection, monitoring and dynamic changes of specific antibodies against SEF14 fimbriae of Enteritidis Salmonella can accurately reflect the presence of SE Ssq strain in infected mice after norfloxacin treatment, thereby accurately evaluating the efficacy of norfloxacin against Enteritidis Salmonella in vivo. This evaluation method can be extended to the accurate evaluation of the efficacy of all different strains of Enteritidis Salmonella in humans and different animals after different intervention measures.

[0007] Technical solution: In order to solve the above technical problems, the present invention provides the use of the Enteritidis Salmonella strain Ssq in constructing a mouse infection model for evaluating the in vivo therapeutic efficacy of norfloxacin.

[0008] The mouse infection model is constructed by infecting animals with the enteritis Salmonella strain Ssq and then treating them with norfloxacin.

[0009] The MIC value of the Enteritidis Salmonella Ssq strain to norfloxacin was determined to be 0.039 μg / mL by in vitro microdilution drug sensitivity test, indicating in vitro sensitivity to norfloxacin.

[0010] Wherein, the dosage of the enteritidis Salmonella strain Ssq is 1×10 4 CFU.

[0011] The application includes monitoring the agglutination titer level and dynamic change results of SEF14 fimbriae-specific antibodies of Enteritidis Salmonella in mice infected with the Enteritidis Salmonella strain Ssq to evaluate the therapeutic efficacy of norfloxacin in vivo.

[0012] The present invention also includes a method for constructing a mouse infection model for evaluating the therapeutic efficacy of norfloxacin in vivo, wherein the construction method comprises orally infecting mice with the enteritidis Salmonella strain Ssq and then orally administering norfloxacin to obtain the infection model.

[0013] Wherein, the dosage of the enteritidis Salmonella strain Ssq is 1×104 CFU.

[0014] The construction method includes monitoring the agglutination titer level and dynamic change results of SEF14 fimbriae-specific antibodies of Enteritidis Salmonella in mice infected with the Enteritidis Salmonella strain Ssq to evaluate the therapeutic efficacy of norfloxacin.

[0015] The construction method specifically comprises the following steps:

[0016] 1) After the mice were infected with the Enteritidis Ssq strain, the Enteritidis Ssq strains were isolated, identified and counted from the spleen, kidney, cecum and ileum of the infected mice on days 2, 5, 10, 15 and 30, and the number of strains was obtained respectively;

[0017] 2) After the mice are infected with the Enteritidis Salmonella Ssq strain, they are treated with norfloxacin on the 5th day of infection. The Enteritidis Salmonella Ssq strains are isolated, identified and counted from the spleen, kidney, cecum and ileum of the infected mice on the 10th, 15th and 30th days, respectively, and compared with the number of infected strains on the 10th, 15th and 30th days in step 1). If the number of strains gradually decreases, it means that the therapeutic effect of norfloxacin is gradually improving. If the number of strains remains the same or increases, it means that the therapeutic effect of norfloxacin is poor. If the number of strains is finally zero, it means that the therapeutic effect of norfloxacin is the best.

[0018] The construction method specifically comprises the following steps:

[0019] (1) After the mice were infected with the Enteritidis Ssq strain, the levels of SEF14 fimbriae-specific antibodies were detected and recorded starting on the 3rd day and continuing until the 30th day;

[0020] (2) After the mice are infected with the enteritis Salmonella strain Ssq, they are treated with norfloxacin on the 5th day of infection, and the level of SEF14 fimbriae-specific antibodies is detected and recorded from the 3rd day and continued to the 30th day; compared with the specific antibody level of SEF14 fimbriae on the corresponding days in step (1), if the antibody level shows a gradual decrease, the therapeutic effect of norfloxacin is gradually improving; if the antibody level remains the same or increases, it means that the therapeutic effect of norfloxacin is not good or gradually worsens; if the antibody level is finally zero, it means that the bacteria are completely eliminated in the body, and the in vivo therapeutic effect of norfloxacin is the best.

[0021] Among them, the detection of SEF14 fimbriae-specific antibody levels is carried out by using the recombinant bacteria S9H+pBR-Sef14 expressing the SEF14 antigen, a virulence factor of Enteritidis Salmonella, based on the SEF14 antigen-antibody agglutination reaction directly mediated by the SEF14 antigen, a virulence factor of Enteritidis Salmonella, to react with the above-mentioned animal serum through agglutination reaction and measure the agglutination antibody titer.

[0022] The specific contents of the in vitro norfloxacin-sensitive Salmonella enteritidis Ssq strain-infected mice specific and convenient evaluation method of the efficacy of norfloxacin in vitro include the following aspects:

[0023] (1) 1×10 4 CFU SE Ssq strain was orally infected into mice, and SE Ssq strain was isolated and identified in the infected mice. The bacteria were isolated and identified in the spleen, kidney, cecum and ileum of the infected mice on days 2, 5, 10, 15 and 30.

[0024] (2)1×10 4 After oral infection of mice with CFU SE Ssq strain, SESsq strain was isolated and identified in the infected mice under norfloxacin treatment. Among them, SESsq strain was isolated and identified in the spleen, kidney, cecum and ileum of infected mice only on days 2 and 5, while SE Ssq strain was not isolated in the spleen, kidney, cecum and ileum on days 10, 15 and 30.

[0025] (3) The detection method based on the specific antibodies of SEF14 fimbriae of Enteritidis can detect and monitor the specific antibodies of SEF14 fimbriae of Enteritidis infected mice, but has no specific cross-reaction with the serum antibodies in mice infected with Salmonella typhimurium, Salmonella pullorum and Escherichia coli.

[0026] (4)1×10 4 CFU SE Ssq strain was orally infected with SEF14-specific antibodies in mice. 4 Mice were orally infected with CFU and the detection and monitoring method of SEF14 fimbriae-specific antibodies of Enteritidis was used. SEF14 fimbriae-specific antibodies were detected starting from the 3rd day and lasted until the 30th day, and the antibody titer level continued to increase in the infected mice.

[0027] (5)1×10 4 After mice were orally infected with CFU SE Ssq strain, under norfloxacin treatment, SEF14 fimbrial-specific antibodies were detected starting on the 3rd day using the detection and monitoring method for SEF14 fimbrial-specific antibodies of Enteritidis. The antibodies began to decrease on the 10th day and disappeared on the 30th day.

[0028] (6) The dynamic changes of SEF14 antibodies in the mice were consistent with the isolation, identification and counting results of mice infected with the oral SE Ssq strain.

[0029] The present invention also includes a specific and convenient evaluation method for the efficacy of norfloxacin in mice infected with the in vitro norfloxacin-sensitive Enteritidis Salmonella Ssq strain, which is applied to the accurate evaluation of different in vitro Enteritidis Salmonella strains.

[0030] The present invention also includes a specific evaluation method for the efficacy of antibiotics in mice infected with in vitro sensitive Salmonella enteritidis, which is applied to the accurate evaluation of Salmonella enteritidis in different animals and humans.

[0031] Mechanism of the present invention: The Enteritidis Salmonella Ssq (SE Ssq) strain of the present invention is highly sensitive to norfloxacin by in vitro minimum inhibitory concentration (MIC) test. The SE Ssq strain orally infects mice, and through the classic Enteritidis Salmonella isolation, identification and counting method, SE Ssq can be isolated and identified in tissue samples of infected mice within 30 days, proving that the SE Ssq strain persists in mice and exists in large quantities, and mice are susceptible. At the same time, the detection method of SEF14 fimbriae-specific antibodies of Enteritidis was used, and the levels of SEF14 fimbriae-specific antibodies and agglutination antibodies in infected mice could be detected and monitored from the 3rd day of infection and continued until the 30th day, and the antibody titer continued to rise with the infection time; in the infected mouse experiment, after oral treatment with 104 mg / kg of norfloxacin on the 5th day, the SE Ssq strain could not be isolated from the infected mice from the 10th day using the classic Salmonella Enteritidis isolation, identification and counting method, proving that the SE Ssq strain was cleared from the infected mice after 10 days of norfloxacin treatment. Similarly, based on the detection and monitoring method of SEF14 fimbriae-specific antibodies of Enteritidis, SEF14 fimbriae-specific antibodies were detected from the 3rd day, and the antibody agglutination titer began to decrease on the 10th day, and continued to decrease until the antibody titer disappeared on the 30th day. Since the SE Ssq strain and its virulence factor SEF14 fimbriae co-exist in the infected mice, the specific immune response of the SEF14 fimbriae antigen in the infected mice, the production of fimbriae-specific antibodies, and the dynamic changes in antibody titer are consistent with the presence, proliferation or disappearance of the SE Ssq strain in the infected mice. The detection, monitoring and dynamic changes of specific antibodies based on SEF14 fimbriae-specific antibodies of Enteritidis Salmonella can accurately reflect the presence of the SE Ssq strain in infected mice, and can accurately evaluate the efficacy of norfloxacin against Enteritidis Salmonella in vivo. This evaluation method can be extended to the specific and accurate evaluation of the efficacy of all different strains of Enteritidis Salmonella in humans and different animals after different intervention measures.

[0032] Beneficial effect: Compared with the existing in vivo antibiotic efficacy evaluation method, the in vitro norfloxacin-sensitive Salmonella enteritidis-infected mice of the present invention is a specific evaluation method for the efficacy of norfloxacin in mice, which realizes the accurate evaluation of the efficacy of norfloxacin on Salmonella enteritidis in mice, and can be further applied to the evaluation of different Salmonella enteritidis in vitro and extended to the evaluation of Salmonella enteritidis in different animals and humans. The present invention specifically uses an in vitro norfloxacin-sensitive Salmonella enteritidis Ssq strain, based on the detection method of Salmonella enteritidis SEF14 fimbriae-specific antibodies, to detect and monitor SEF14 fimbriae-specific antibodies in mice infected with Salmonella enteritidis Ssq strains, and at the same time adopts the classic Salmonella enteritidis isolation, identification and counting method, reflecting that SEF14 fimbriae antigen-specific immune response, fimbriae-specific antibody production and Salmonella enteritidis Ssq strain co-exist in infected mice. The dynamic changes of Salmonella enteritidis SEF14 fimbriae-specific antibodies reflect the presence of SE Ssq strains in infected mice. The detection, monitoring and dynamic changes of specific antibodies against SEF14 fimbriae of Enteritidis Salmonella can accurately reflect the presence of SE Ssq strain in infected mice and accurately evaluate the efficacy of norfloxacin against Enteritidis Salmonella in vivo. This evaluation method can be extended to the specific and accurate evaluation of the efficacy of all different strains of Enteritidis Salmonella in humans and different animals after different intervention measures. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 Oral infection 1×10 4 CFU of Enteritidis Ssq strain isolated, identified and counted from spleen, kidney, cecum and ileum of mice on days 2, 5, 10, 15 and 30.

[0034] Figure 2 Oral infection 1×10 4 CFU of Enteritidis Ssq strain mice were isolated, identified and counted from spleen, kidney, cecum and ileum on days 2, 5, 10, 15 and 30 under norfloxacin treatment.

[0035] Figure 3 Oral infection 1×10 4 Results of monitoring of SEF14-specific antibodies in mice with CFU Enteritidis Ssq strain.

[0036] Figure 4 Oral infection 1×10 4 Results of SEF14-specific antibody monitoring in CFU Enteritidis Ssq strain mice treated with norfloxacin. DETAILED DESCRIPTION

[0037] The present invention will be further described below in conjunction with the accompanying drawings and embodiments.

[0038] The Salmonella Enteritidis Ssq strain (SE Ssq) involved in the present invention is called the live vaccine of Salmonella Enteritidis Sm24 / Rif12 / Ssq strain, which is purchased from Tianjin Ruipu Company.

[0039] The norfloxacin involved in the present invention was purchased from Beijing Solaibao Technology Co., Ltd.

[0040] Example 1 In vitro MIC test confirmed that SE Ssq strain is highly sensitive to norfloxacin

[0041] The SE Ssq strain was taken out from the -80°C freezer and rejuvenated, and diluted 1:100 by volume using PBS buffer (0.01 mol / L, pH 7.0) to a final concentration of 1×10 5 CFU / mL, use a pipette to draw 100μL and add it to a 96-well plate. Then add 100μL of 1280μg / mL norfloxacin to the third column of the 96-well plate, and add 100μL PBS buffer (0.01mol / L, PH7.0) to the second column as a negative control. Use a pipette to dilute from the third column in sequence according to the two-fold dilution method, draw 100μL from the last column, and then incubate at 37°C for 24h and observe with the naked eye. The lowest antibiotic concentration with no visible bacterial growth is the MIC value of norfloxacin for Salmonella enteritidis.

[0042] The above in vitro norfloxacin sensitivity results showed that the MIC value of the Ssq strain of Salmonella Enteritidis to norfloxacin in vitro was 0.039 μg / mL, indicating that it was sensitive to norfloxacin in vitro.

[0043] Example 2 1×10 4 Isolation and identification of SE Ssq strain in mice orally infected with CFU of SE Ssq strain

[0044] Thirty 6-week-old BALB / c mice were purchased from the College of Veterinary Medicine (Comparative Medicine) of Yangzhou University and divided into five groups, with 6 mice in each group. 4 Mice were orally infected with the CFU dose SE Ssq strain and euthanized on days 2, 5, 10, 15, and 30 after infection. The spleen, kidney, cecum, and ileum of the mice were weighed, ground, and diluted in PBS buffer (0.01 mol / L, pH 7.0) at a volume ratio of 1:100. The bacteria were cultured on the selective MacConkey agar (MAC) medium produced by Beijing Solebow Technology Co., Ltd. for bacterial isolation and identification, and the bacterial load in the spleen, kidney, cecum, and ileum was further determined.

[0045] Figure 1 The results showed that 1×10 4Mice were orally infected with CFU SE Ssq strain, and SE Ssq strain could be isolated and identified in the spleen, kidney, cecum and ileum of the infected mice on the 2nd, 5th, 10th, 15th and 30th days, proving that SE Ssq strain persists in the mice.

[0046] Example 3 1×10 4 Isolation and identification of SE Ssq strain in mice orally infected with CFU of SE Ssq strain under norfloxacin treatment

[0047] Thirty 6-week-old BALB / c mice were purchased from the College of Veterinary Medicine (Comparative Medicine) of Yangzhou University and divided into five groups, with 6 mice in each group. 4 CFU dose was orally administered to mice infected with SE Ssq strain. According to the equivalent dose coefficient conversion method in accordance with the "Pharmacopoeia of the People's Republic of China", norfloxacin was calculated as a daily dose of 104 mg / kg for mice for treatment. Euthanasia was performed on days 2, 5, 10, 15 and 30 after infection, and the spleen, kidney, cecum and ileum of mice were weighed, ground and crushed, and then diluted in PBS buffer (0.01 mol / L, PH7.0) in accordance with the volume of 1:100, and cultured in selective MacConkey agar medium (MAC) of Beijing Solebow Technology Co., Ltd. for bacterial isolation, identification and counting, and further determination of the bacterial load in the spleen, kidney, cecum and ileum.

[0048] Figure 2 The results showed that 1×10 4 Mice were orally infected with CFU SE Ssq strain. The SE Ssq strain could be isolated and identified in the spleen, kidney, cecum and ileum of the infected mice on the 2nd and 5th days, while the SE Ssq strain could not be isolated from the spleen, kidney, cecum and ileum on the 10th, 15th and 30th days, indicating that the SE Ssq strain was completely eliminated from the mice after norfloxacin treatment, and the therapeutic effect was optimal.

[0049] Example 4 Detection method of specific antibodies to SEF14 fimbriae of Salmonella enteritidis

[0050] 1. Preparation of recombinant bacteria (S9H+pBR-Sef14) expressing SEF14 fimbriae virulence factors of Salmonella enteritidis

[0051] The present invention relates to a method for detecting specific antibodies to SEF14 pili of Salmonella enteritidis, based on a specific positive agglutination reaction between a recombinant bacterium (S9H+pBR-Sef14) expressing a virulence factor of SEF14 pili of Salmonella enteritidis and the serum of mice infected with Salmonella enteritidis, wherein the S9H+pBR-Sef14 recombinant bacterium is obtained by inserting the sef14 operon gene of Salmonella enteritidis into an expression vector pBR322 and then introducing the inert carrier bacterium S9H, and the inert carrier bacterium S9H and the control system strain S9H+pBR refer to the Chinese invention patent of "a pan-type inert carrier Salmonella and its potential application", with the patent number of ZL202010427735.8. The construction method of the recombinant strain S9H+pBR-Sef14 refers to the patent number of ZL202011289887.2, which has obtained a national invention patent, and the invention name is a recombinant bacterium expressing SEF14 functional pili and its application.

[0052] Based on the construction, verification and preservation of the recombinant strain S9H+pBR-Sef14 and the control system strain S9H+pBR (empty vector strain) in our laboratory, the two strains were cultured to 5×10 9 CFU / mL. 4000r / min, centrifuge for 5min, discard the supernatant, wash with an equal amount of sterile PBS for 3 times, and dispense into finger-shaped tubes and store at 4℃ for later use. S9H+pBR bacterial suspension is the control antigen, and S9H+pBR-Sef14 bacterial suspension is the test antigen.

[0053] 2. Detection of SEF14 fimbriae-specific antibodies against SEF14 fimbriae mediated by recombinant bacteria S9H+pBR-Sef14 expressing SEF14 fimbriae virulence factors of SEF14

[0054] Place the serum to be tested and the S9H+pBR and S9H+pBR-Sef14 agglutination antigens in a clean bench (20-25°C) and warm them up for 20 minutes. Before testing, use a pipette to gently mix all antigens until there is no precipitation. First, use a pipette to take 6μL of the serum to be tested, drop it vertically on the slide, change the gun tip, take an equal amount of antigens and drop them vertically into the serum droplets, use the gun tip to fully mix the bacterial liquid and serum, and spread them into a sheet with a diameter of about 1-2cm. Then immediately shake the glass plate steadily and determine the result within 2 minutes. If S9H+pBR has no agglutination particles and S9H+pBR-Sef14 agglutination antigens all have agglutination particles, it is judged as a positive reaction; if none of the above antigens have agglutination particles, it is judged as a negative reaction.

[0055] The positive sera from mice infected with the standard strain of Salmonella typhimurium sl1344, the standard strain of Salmonella Enteritidis SE 50336, the standard strain of Salmonella pullorum CVCC 535, the vaccine strain of Salmonella Gallinarum SG01 and the isolate of Escherichia coli APEC XM were all obtained from artificially infected animals in our laboratory.

[0056] Table 1 Specificity detection and verification results of SEF14 fimbriae-specific antibodies of SEF14 of S. enteritidis mediated by recombinant bacteria S9H+pBR-Sef14 expressing SEF14 fimbriae virulence factors of S. enteritidis

[0057]

[0058]

[0059] Note: + indicates that the serum produces a specific agglutination reaction with the Sef14 antigen; - indicates that the serum does not produce a specific agglutination reaction with the Sef14 antigen

[0060] The results in Table 1 show that the Sef14 antigen expressed by S9H+pBR-Sef14 only agglutinates with the positive serum of Salmonella Enteritidis; it does not agglutinate with the positive serum infected with Salmonella Typhimurium, Salmonella Pullorum, Salmonella Gallinarum and Escherichia coli.

[0061] Example 5 1×10 4 Monitoring of SEF14 fimbriae-specific antibodies in mice orally infected with CFU of SE Ssq strain

[0062] Six 6-week-old BALB / c mice were purchased from the College of Veterinary Medicine (Comparative Medicine) of Yangzhou University and 1×10 4 The mice were infected with SE Ssq strain orally at a CFU dose, and the mouse serum was obtained by orbital venous blood collection on days 5, 10, 15, 20, 25 and 30 of infection. The serum was kept still in a 37°C incubator for 30 minutes, and then centrifuged at 3000 rpm for 5 minutes, and the supernatant was marked. The recombinant bacteria S9H+pBR-Sef14 expressing the enteritidis virulence factor SEF14 antigen was used to agglutinate the above mouse serum to determine whether there were visible agglutination particles, and the serum was diluted twice to detect the agglutination titer of the antibody against the SEF14 specific target antigen and the dynamic change results were analyzed.

[0063] Figure 3 The results show that 1×10 4SEF14 fimbrial antibodies can be specifically detected as early as the third day after oral infection with the in vitro sensitive Enteritidis Salmonella SE Ssq strain at a CFU dose and last until the 30th day, and the antibody titer continues to increase. During this process, the dynamic changes of SEF14 fimbrial antibodies in mice are consistent with the isolation and identification results of the above-mentioned oral infection SE Ssq strain mice.

[0064] Example 6 1×10 4 Monitoring of SEF14-specific antibodies in mice orally infected with CFU of SE Ssq strain under norfloxacin treatment

[0065] Six 6-week-old BALB / c mice were purchased from the College of Veterinary Medicine (Comparative Medicine) of Yangzhou University and 1×10 4 CFU dose SE Ssq strain was orally infected with mice. On the 5th day of infection, the daily dose of norfloxacin was calculated as 104 mg / kg for mice according to the equivalent dose coefficient conversion method in accordance with the "National Pharmacopoeia of the People's Republic of China". Mouse serum was obtained by orbital venous blood collection on days 5, 10, 15, 20, 25 and 30 of infection, and the serum was kept still in a 37°C incubator for 30 minutes, then centrifuged at 3000 rpm for 5 minutes, and the supernatant was marked. The recombinant bacteria S9H+pBR-Sef14 expressing the enteritidis virulence factor SEF14 antigen was used to agglutinate the above mouse serum to determine whether there were visible agglutination particles, and the serum was diluted twice to detect the agglutination titer of the antibody against the SEF14 specific target antigen and the dynamic change results were analyzed.

[0066] Figure 4 The results show that 1×10 4 SEF14 fimbriae-specific antibodies were detected as early as the 3rd day after oral infection with in vitro sensitive Enteritidis Salmonella SE Ssq strain at a CFU dose. The antibodies began to decrease on the 10th day and disappeared on the 30th day. The dynamic changes of SEF14 antibodies in mice were consistent with the isolation, identification and counting results of mice infected with oral SE Ssq strains under treatment, demonstrating that the therapeutic efficacy can be monitored by changes in SEF14 antibodies.

[0067] In summary, a specific and convenient method for evaluating the efficacy of norfloxacin in mice infected with the in vitro norfloxacin-sensitive Salmonella enteritidis Ssq strain of the present invention is described. The present invention is not limited to the above embodiments. The above embodiments and the specification only describe the method of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements are required to be within the scope of the present invention. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. Application of Enteritidis Salmonella Ssq strain in constructing a mouse infection model to evaluate the therapeutic efficacy of norfloxacin in vivo.

2. The use according to claim 1, characterized in that: The mouse infection model is constructed by infecting mice with the Enteritidis Salmonella strain Ssq and then orally treating them with norfloxacin.

3. The use according to claim 2, characterized in that: The amount of the enteritidis Salmonella strain Ssq is 1×10 4 CFU.

4. The use according to claim 1 or 2, characterized in that: The application includes monitoring the agglutination titer level and dynamic change results of SEF14 pili-specific antibodies of S. enteritidis in mice infected with the Ssq strain of S. enteritidis to evaluate the therapeutic efficacy of norfloxacin in the mice.

5. A method for constructing an infected mouse model for evaluating the therapeutic efficacy of norfloxacin in vivo, characterized in that: The construction method comprises the steps of orally infecting mice with the enteritidis Salmonella strain Ssq and then orally treating the mice with norfloxacin.

6. The construction method according to claim 5, characterized in that: The amount of the enteritidis Salmonella strain Ssq is 1×10 4 CFU.

7. The construction method according to claim 5, characterized in that: The construction method includes monitoring the agglutination titer level and dynamic change results of the specific antibody of SEF14 pili of Enteritidis to evaluate the therapeutic efficacy of norfloxacin in mice infected with Enteritidis Salmonella strain Ssq.

8. The construction method according to claim 5, characterized in that: The construction method specifically comprises the following steps: 1) After the mice were infected with the Enteritidis Ssq strain, the spleen, kidney, cecum and ileum of the infected mice were isolated, identified and counted on the 2nd, 5th, 10th, 15th and 30th days, and the number of Enteritidis Ssq strains was obtained respectively; 2) After the mice are infected with the Enteritidis Salmonella Ssq strain, they are treated with norfloxacin on the 5th day after infection. The Enteritidis Salmonella Ssq strain is isolated and identified from the spleen, kidney, cecum and ileum of the infected mice on the 10th, 15th and 30th days, respectively, and compared with the number of Enteritidis Salmonella Ssq strains infected on the 10th, 15th and 30th days in step (1). If the number of strains gradually decreases, it means that the therapeutic effect of norfloxacin is gradually improving. If the number of strains remains the same or increases, it means that the therapeutic effect of norfloxacin is poor. If the number of strains is finally zero, it means that the bacteria are completely eliminated from the body and the therapeutic effect of norfloxacin is the best.

9. The construction method according to claim 5, characterized in that: The construction method specifically comprises the following steps: (1) After the mice were infected with the Enteritidis Ssq strain, the agglutination titer of SEF14 fimbriae-specific antibodies was monitored and recorded starting on the 3rd day and continuing until the 30th day; (2) After the mice are infected with the enteritis Salmonella strain Ssq, they are treated with norfloxacin on the 5th day of infection, and the agglutination titer level of the SEF14 fimbriae-specific antibody is monitored and recorded from the 3rd day and continued to the 30th day; compared with the specific antibody level of the SEF14 fimbriae on the corresponding days in step (1), if the antibody level shows a gradual decrease, the therapeutic effect of norfloxacin is gradually improved, if the antibody level remains the same or increases, it indicates that the therapeutic effect of norfloxacin is poor, and if the antibody level finally reaches zero, it indicates that the bacteria are completely eliminated from the body and the therapeutic effect of norfloxacin is the best.

10. The construction method according to claim 7, characterized in that: The monitoring of the agglutination titer level of the SEF14 fimbriae-specific antibody is carried out by using the recombinant bacteria S9H+pBR-Sef14 expressing the SEF14 antigen of the virulence factor of Enteritidis and the mouse serum to directly mediate the agglutination reaction through the SEF14 antigen of the virulence factor and then measure the titer.